Thomas G, Dembo A, Beale F, Bean H, Bush R, Herman J, Pringle J, Rawlings G, Sturgeon J, Fine S
Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1785-90. doi: 10.1016/0360-3016(84)90550-9.
Between July 1981 and June 1983, 27 patients with advanced primary squamous cell carcinoma (SCC) of cervix (FIGO Stages IIIB, IVA or extensive nodal involvement) and 8 with recurrent disease were treated using a pilot regimen of combination chemotherapy (CT): Mitomycin C (MIT), 5 Fluorouracil (5 FU), and radiation therapy (RT). CT and RT doses on this Phase I-II Study were escalated to the current regimen. A split course of RT was used, either pelvic RT alone (4560 Gy in 28 fractions) or the same pelvic RT plus para-aortic RT (3600 Gy in 24 fractions). CT was given: MIT 6 mg/M2 IV push day 1, and 5 FU 1.0 g/M2 (maximum daily 1.5 g) by continuous IV infusion days 1 through 4 of each half-course of RT. This was followed by one application of intrauterine 137Cs when possible. Three of the 8 patients with recurrence in the pelvis or para-aortic nodes had a complete response (CR) to CT-RT and are alive without disease at 19, 19 and 22 months after treatment, respectively. Twenty of the 27 (74%) primary patients had a CR. With a median duration of follow-up of 6 months 4/20 have relapsed, 1 in RT field, 2 at distant sites, and 1 in both. Pelvic disease remains controlled in 19/27 (70%) including one patient salvaged with surgery. The acute toxicity of this regimen was tolerable: 2/35 developed transient leukopenia with one febrile episode, 9/35 developed transient thrombocytopenia without bleeding. Symptomatic sigmoid strictures developed in two patients, one requiring surgical intervention. Sigmoid perforation occurred in one patient and contributed to death. Typically, near complete regression of tumor is noted on completion of the external RT, reproducing the dramatic responses that have been observed in SCC of the anal canal, esophagus and head and neck, with this CT-RT regimen. A Phase III Study is required to establish whether the enhanced response rates to CT-RT will result in increased pelvic control and cure rates compared to those after RT alone.
1981年7月至1983年6月期间,27例晚期原发性子宫颈鳞状细胞癌(SCC)患者(国际妇产科联盟(FIGO)分期为IIIB期、IVA期或广泛淋巴结受累)和8例复发性疾病患者接受了联合化疗(CT)和放射治疗(RT)的试验性方案治疗:丝裂霉素C(MIT)、5-氟尿嘧啶(5-FU)。在这项I-II期研究中,CT和RT剂量逐步增加至当前方案。采用分段放疗,单独盆腔放疗(28次分割,45~60 Gy)或相同的盆腔放疗加腹主动脉旁放疗(24次分割,36 Gy)。CT给药方案为:第1天静脉推注MIT 6 mg/m²,在每个放疗半程的第1~4天通过静脉持续输注给予5-FU 1.0 g/m²(最大每日1.5 g)。之后尽可能进行一次宫腔内137Cs治疗。8例盆腔或腹主动脉旁淋巴结复发患者中有3例对CT-RT完全缓解(CR),分别在治疗后19、19和22个月无病存活。27例原发性患者中有20例(74%)达到CR。中位随访6个月时,20例CR患者中有4例复发,1例在放疗野内,2例在远处部位,1例在两者均有复发。27例中有19例(70%)盆腔疾病得到控制,其中1例通过手术挽救。该方案的急性毒性是可耐受的:35例中有2例出现短暂性白细胞减少,伴有1次发热发作,35例中有9例出现短暂性血小板减少但无出血。2例患者出现症状性乙状结肠狭窄,1例需要手术干预。1例患者发生乙状结肠穿孔并导致死亡。通常,在体外放疗完成时可观察到肿瘤几乎完全消退,与肛管、食管和头颈部SCC中观察到的显著反应相似,采用这种CT-RT方案。需要进行III期研究以确定与单纯放疗后相比,CT-RT提高的反应率是否会导致盆腔控制率和治愈率增加。